Treatment of the critically ill patient with protein C: Is it worth the cost?

Thrombosis Research

Volumn 125, Issue 6, 2010, Pages 494-500

  Nilsson, Gunnar ^a   Höjgård, Sören ^b   Berntorp, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Critical care; Health care costs; Intensive care units; Medical economics; Protein C; Survival analysis

Indexed keywords

ANTITHROMBIN; DROTRECOGIN; PROTEIN C;

ADULT; AGED; APACHE; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DRUG COST; FEMALE; HUMAN; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; SURVIVAL; SURVIVAL RATE; THROMBOCYTE COUNT; CRITICAL ILLNESS; ECONOMICS; HEMOSTATIC DISORDERS; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; MIDDLE AGED; STATISTICAL MODEL;

AGED; COST-BENEFIT ANALYSIS; CRITICAL ILLNESS; FEMALE; HEMOSTATIC DISORDERS; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROTEIN C; SURVIVAL ANALYSIS; KAPLAN-MEIER ESTIMATE;

EID: 77952553093     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.09.008     Document Type: Article

References (39)

1. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., and Fisher Jr. C.J. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
2. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., Cohen J., Opal S.M., Vincent J.L., and Ramsay G. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003) 1250-1256
3. Abraham E., Laterre P.F., Garg R., Levy H., Talwar D., Trzaskoma B.L., Francois B., Guy J.S., Bruckmann M., Rea-Neto A., Rossaint R., Perrotin D., Sablotzki A., Arkins N., Utterback B.G., and Macias W.L. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
4. White B., Livingstone W., Murphy C., Hodgson A., Rafferty M., and Smith O.P. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96 (2000) 3719-3724
5. Mesters R.M., Helterbrand J., Utterback B.G., Yan S.B., Chao Y.B., Fernandez J.A., Griffin J.H., and Hartman D.L. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28 (2000) 2209-2216
6. Yan S.B., Helterbrand J.D., Hartman D.L., Wright T.J., and Bernard G.R. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120 (2001) 915-922
7. Nilsson G., Astermark J., Lethagen S., Vernersson E., and Berntorp E. Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival. Thromb Res 116 (2005) 15-24
8. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980. p. 12-20, 70-119.
9. Collett D. Modelling survival data in medical research. London: Chapman and Hall; 1997. p. 15-31, 53-106, 223-37.
10. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985) 818-829
11. Blossfeld H.M., Hamerle A., and Mayer K.U. Event history analysis (1989), Lawrence Erlbaum Associates, New Jersey p. 89-91
12. SPSS Statistics 17.0. Homepage on the Internet; cited 2009 February 16. SPSS Inc, Headquarters. Wacker Drive, Chicago, IL, USA. Available from: http://www.spss.com/statistics.
13. LIMDEP version 9.0. Homepage on the Internet; cited 2009 February 16. Econometric Software, Inc. Gloria Place, Plainview, NY, USA. Available from: http://www.limdep.com.
14. SAS/STAT 9.2. Homepage on the Internet; cited 2009 February 16. SAS Institute Inc. SAS Campus Drive, Cary, NC, USA. Available from: http://support.sas.com/rnd/app/da/new/dastat92.html.
15. STATA 10. Homepage on the Internet; cited 2009 February 16. StataCorp LP. Lakeway Drive, College Station, TX, USA. Available from: http://www.stata.com.
16. FASS (Pharmaceutical specialities in Sweden). Homepage on the Internet; cited 2007 July 11. Sweden. Available from: http://www.fass.se.
17. Heyland D.K., Gafni A., Griffith L., Cook D., Marshall J., Fuller H., Todd T., Guslits B., Heule M., Hewson J., Lacroix J., Noseworthy T., and Powles P. The clinical and economic consequences of clinically important gastrointestinal bleeding in critically ill patients. Clin Intensive Care 7 (1996) 121-125
18. Viscusi W.K. Fatal tradeoffs: public and private responsibilities for risk (1992), Oxford University Press, New York p. 19-21
19. Persson U., Norinder A., Hjalte K., and Gralén K. The value of a statistical life in transport: findings from a new contingent valuation study in Sweden. J Risk Uncertain 23 (2001) 121-134
20. Viscusi W.K. The value of risks to life and health. J Econ Lit 31 (1993) 1912-1946
21. Viscusi W.K., and Aldy J.E. The value of a statistical life: A critical review of market estimates throughout the world. J Risk Uncertain 27 (2003) 5-76
22. Baker R., Chilton S., Jones-Lee M., and Metcalf H. Valuing lives equally: Defensible premise or unwarranted compromise?. J Risk Uncertain 36 (2008) 125-138
23. Alberini A., Cropper M., Krupnick A., and Simon N.B. Does the value of a statistical life vary with age and health status? Evidence from the United States and Canada. Resources for the Future. Discussion paper No. 02-19 (2002)
24. de Blaeij A., Koetse M., Tseng Y., Rietveld P., and Verhoef E. Valuation of safety, time, air pollution, climate change, and noise: methods and estimates for various countries. Report for the EU project ROSEBUD (2004), Vrije Universiteit, Amsterdam
25. Vincent J.L., Bernard G.R., Beale R., Doig C., Putensen C., Dhainaut J.F., Artigas A., Fumagalli R., Macias W., Wright T., Wong K., Sundin D.P., Turlo M.A., and Janes J. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266-2277
26. Dahabreh Z., Dimitriou R., Chalidis B., and Giannoudis P.V. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma. Expert Opin Drug Saf 5 (2006) 67-82
27. de Kleijn E.D., de Groot R., Hack C.E., Mulder P.G., Engl W., Moritz B., Joosten K.F., and Hazelzet J.A. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31 (2003) 1839-1847
28. Faust S.N., Levin M., Harrison O.B., Goldin R.D., Lockhart M.S., Kondaveeti S., Laszik Z., Esmon C.T., and Heyderman R.S. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345 (2001) 408-416
29. Liaw P.C. Endogenous protein C activation in patients with severe sepsis. Crit Care Med 32 (2004) S214-S218 [Suppl.]
30. Davies A., Ridley S., Hutton J., Chinn C., Barber B., and Angus D.C. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 60 (2005) 155-162
31. Green C., Dinnes J., Takeda A.L., and Cuthbertson B.H. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 22 (2006) 90-100
32. Riou França L., Launois R., Le Lay K., Aegerter P., Bouhassira M., Meshaka P., and Guidet B. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care 22 (2006) 101-108
33. Frampton J.E., and Foster R.H. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis. Pharmacoeconomics 22 (2004) 445-476
34. Neilson A.R., Burchardi H., Chinn C., Clouth J., Schneider H., and Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 18 (2003) 217-227
35. Angus D.C., Linde-Zwirble W.T., Clermont G., Ball D.E., Basson B.R., Ely E.W., Laterre P.F., Vincent J.L., Bernard G., and van Hout B. PROWESS Investigators. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31 (2003) 1-11
36. Manns B.J., Lee H., Doig C.J., Johnson D., and Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347 (2002) 993-1000
37. Hjelmgren J., Persson U., and Tennvall G.R. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. Am J Ther 12 (2005) 425-430
38. Eichacker P.Q., and Natanson C. Increasing evidence that risks of rhAPC may outweigh its benefits. Intensive Care Med 33 (2007) 396-399
39. Williams M.D., Macias W., and Rustige J. Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. Intensive Care Med 33 (2007) 1487-1488